Recursion Pharmaceuticals, Inc. (RXRX) Misses Q4 EPS by 12c
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.53), $0.12 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $4.55 million versus the consensus estimate of $13.4 million.
For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Nutrien warns shareholders about below-market mini-tender offer
- Independence Realty Trust (IRT) files mixed shelf
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
